That's what happened beginning in November of last year, anyway. The company announced solid testing results for VK2735. But ...

Modern weight loss medications represent a breakthrough, but they are most effective when combined with the right lifestyle strategies. Here's what that looks like.

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body weight in a late-stage study in ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

A glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor dual agonist developed by Jiangsu Hengrui Pharmaceuticals Co. Ltd. and licensed by Kailera Therapeutics Inc. has ...